Patient-Specific Therapeutic Vaccines for Metastatic Melanoma

Oncology Issues

Volumn 30, Issue 2, 2015, Pages 48-57

  Dillman, Robert O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84966313316     PISSN: 10463356     EISSN: 25731777     Source Type: Journal    
DOI: 10.1080/10463356.2015.11884014     Document Type: Article

References (78)

1. Balch CM, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206.
2. American Joint Committee on Cancer. Edge SB, Byrd DR, Comton CC, et al, eds. Melanoma of the skin. In AJCC Cancer Staging Handbook, 7th ed.; New York: Springer; 2010;387–415.
3. Chapman PB, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17(9):2745–2751.
4. Middleton MR, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–166.
5. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
6. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated melanoma. N Engl J Med. 2011;364(26):2517–2526.
7. Eton O, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol. 2002;20(8):2045–2052.
8. Atkins MB, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748–5754.
9. Hauschild A, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823–2830.
10. Kim KB, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2011;30(1):34–41.
11. Kaufman HL, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10:588–98.
12. Essner R, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961–966.
13. McLoughlin JM, et al. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008;15(3):239–247.
14. Howard JH, et al. Metastasectomy for distant metastatic melanoma: Analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–2555.
15. Morton DL, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25:474s (abstr 8508).
16. Lawson DH, et al. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage II-IV melanoma. J Clin Oncol. 2010;28:15s (suppl; abstr 8504).
17. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
18. Sosman JA, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafinib. N Engl J Med. 2012;366(8):707–714.
19. Hauschild A, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicenter, open-label phase III randomized controlled trial. Lancet. 2012;380:1893–1901.
20. Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
21. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2010;367(18):1694–1703.
22. Ribas A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: A phase 1b study. Lancet Oncol. 2014;15:954–965.
23. Solit DB, et al. Resistance to BRAF inhibition in melanoms. N Engl J Med. 2011;364:772–774.
24. Frederick DT, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–1231.
25. Dillman RO, et al. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012;27(6):337–343.
26. Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–2116.
27. Atkins MB, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am. 2000;6(suppl 1): S11–S14.
28. Sosman JA, et al. Three phase II Cytokine Working Group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HAL-A2-positive advanced melanoma. J Clin Oncol. 2008;26:2292–2298.
29. Schwartzentruber DJ, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–2127.
30. Eton O, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol. 2002;20(8):2045–2052.
31. Atkins MB, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748–5754.
32. Schwartz RN, et al. Managing toxicities of high-dose interleukin-2. Oncol. 2002;16(11 Suppl 13):11–20.
33. Lindsey KR, et al. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol. 2000;18(9):1954–1959.
34. Dillman RO, et al. High-dose IL-2 in metastatic melanoma: Better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm. 2014;29:53–57.
35. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nature Cancer Reviews. 2012;12:252–264.
36. Dolan DE, et al. PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy. Cancer Control. 2014;21:231–237.
37. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
38. Wolchok JD, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013; 24:2174–2180.
39. Weber J. Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58:823–830.
40. Topolian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
41. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2466.
42. Hamid O, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
43. Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117.
44. Topalian SL, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32,1020–1030.
45. Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
46. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
47. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1–10.
48. Mittal D, et al. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
49. Van Elsas A, et al. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355–366.
50. Li B, et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor—secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15:1623–1634.
51. Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature. 2013;499:214–218.
52. Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747–752.
53. Tran E, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344:641–645.
54. Lu Y-C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20:3401–3410.
55. Dillman RO. Melanoma Vaccines: Trials and Tribulations. Vaccine Dev Ther. 2013;3:57–78.
56. Andtbacka RHI, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 31, 2013 (suppl; abstr LBA9008).
57. Postow MW, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–931.
58. Dillman RO, et al. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother. 1993;14:65–69.
59. Dillman RO, et al. Cancer stem cell antigen-based vaccines: The preferred strategy for active specific immunotherapy of metastatic melanoma? Expert Opin Biol Ther. 2013;13:643–656.
60. Dillman RO, et al. The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer. Cancer Biother Radiopharm. 1999;14:443–449.
61. Dillman RO, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm. 2002;17:51–66.
62. Dillman RO, et al. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004;19:570–580.
63. Dillman RO, et al. Phase I/II trial of autologous tumor cell line-derived vaccine for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004;19:581–588.
64. Dillman RO, et al. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med. 2006;355:1179–1181.
65. Dillman RO, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm. 2007;22:309–321.
66. Dillman RO, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma: Final Report. Cancer Biother Radiopharm. 2009;24:311–319.
67. Dillman RO, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012;35:641–649.
68. Dillman RO, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm. 2010;25:553–557.
69. Dillman RO, et al. 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines. 105th Annual Meeting of the American Association for Cancer Research, 06 April 2014. Proc Am Assoc Cancer Res. 55: 2014. (abstract #197)
70. Tagawa ST, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer. 2006;106:1353–1357.
71. Dillman RO, et al. 5-year survival for patients with detectable metastatic melanoma at time of treatment with patient-specific tumor stem cell vaccines. American Society of Clinical Oncology 50th Annual Meeting, Chicago, IL. 01 June 2014. J Clin Oncol. 32:2014. (abstract #3090).
72. Dillman RO, et al. Tissue banking in community cancer centers. Oncol Issues. 2008;23:22–26.
73. Selvan SR, et al. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res. 2010;20:280–292.
74. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.
75. Spitler LE, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000;18:1614–1621.
76. Spitler LE, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother. 2009;32:632–637.
77. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
78. Schmidt P, et al. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA. 2011;8:108:2474–2479.